Dexmethylphenidate Extended Release

@article{Moen2009DexmethylphenidateER,
  title={Dexmethylphenidate Extended Release},
  author={Marit D. Moen and S. Keam},
  journal={CNS Drugs},
  year={2009},
  volume={23},
  pages={1057-1083}
}
SummaryAbstractDexmethylphenidate extended release (XR) [Focalin® XR] is a CNS stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients aged ≥6 years. Dexmethylphenidate contains the d-threo- enantiomer of methylphenidate. Dexmethylphenidate XR capsules have a bimodal release profile, which mimics two doses of dexmethylphenidate immediate release (IR) given 4 hours apart, and allows once-daily administration.Once-daily dexmethylphenidate XR was… Expand
View on Springer
ncbi.nlm.nih.gov
8 Citations
Background Citations
3
Methods Citations
2

8 Citations

Citation Type

Citation Type

Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
  • 36
An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations
  • 5
Analytically Confirmed Intoxication by 4-Fluoromethylphenidate, an Analog of Methylphenidate.
  • 4
Risk of Serious Cardiovascular Problems with Medications for Attention-Deficit Hyperactivity Disorder
  • 101
Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers.
  • 12
  • PDF
Evolution of stimulants to treat ADHD: transdermal methylphenidate
  • 33
Statistical Methods for Evaluating Relational Structures in Multi-Dimensional Phenotypic Data for Neuropsychiatric Disorders
The nonmedical use of prescription stimulants among dental and dental hygiene students.
  • 60
  • PDF

References

SHOWING 1-10 OF 56 REFERENCES
Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
  • R. Silva, R. Muniz, +4 authors J. Wang
  • Psychology, Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2008
  • 25
Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
  • 24
Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD
  • 52
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
  • 15
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
  • 57
A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder
  • 23
Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate
  • 57
Efficacy and Safety of Dexmethylphenidate Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
  • 140
Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
  • 36
Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
  • 41
...
1
2
3
4
5
...